当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Christian Fiala, Teresa Bombas, Mirella Parachini, Aubert Agostini, Roberto Lertxundi, Marek Lubusky and Kristina Gemzell Danielsson
Introduction: The challenge in medical abortion is to reliably determine success of treatment within a short time interval, with the aim of improving evaluation of medical abortion outcomes. This can be done clinically using ultrasound (US) and/or hCG testing (urine human chorionic gonadotropin). The systematic use of US may lead to unnecessary surgical intervention and may be a barrier to the use of medical abortion when US is not accessible. Furthermore, US cannot be used in case of very early medical abortion with no confirmed intrauterine pregnancy at initiation of treatment. Serum hCG is highly reliable to judge on-going pregnancy and levels detected in urine correlate with serum levels. Self-assessment of the urine hCG test has proven to be effective and highly acceptable to women. The aim of this review is to describe the use of hCG testing for medical abortion outcomes.
Methods: An extensive literature search was performed using MedLine, with keywords “hCG” AND “abortion” and “abortion” AND “follow-up”, to identify publications in English from 2003 to 2016. A total of 910 references were found, out of which 35 including information on hCG testing were considered.
Results: This review confirms that low-sensitivity urine hCG tests are highly reliable for determining medical abortion outcomes up to 63 days gestation. Their high sensitivity and specificity allow for shortening the time interval to accurately determine success of treatment.
Conclusion: Self-assessment using a low-sensitivity urine hCG test is effective in identifying on-going pregnancy while increasing women’s autonomy by reducing in-clinic visits.